Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.39 |
| ▸ | CCKAR | P32238 | 3/20 | 0.36 |
| ▸ | CCKBR | P32239 | 3/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71221 | 0.92 | GLP1R (0.61) | GLP1RNOD1CCKARCCKBRSELP | |
| SCHEMBL19261638 | 0.92 | GLP1R (0.61) | GLP1RNOD1CCKARCCKBRSELP | |
| SCHEMBL71066 | 0.92 | GLP1R (0.58) | GLP1RNOD1CCKARCCKBRSELP | |
| SCHEMBL71225 | 0.89 | GLP1R (0.56) | GLP1RNOD1CCKARCCKBRSELP | |
| SCHEMBL13184655 | 0.89 | GLP1R (0.53) | GLP1RNOD1FOLH1 | |
| SCHEMBL13184654 | 0.88 | GLP1R (0.56) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL14478727 | 0.88 | GLP1R (0.56) | GLP1RNOD1SELPFOLH1 | |
| SCHEMBL8234536 | 0.88 | GLP1R (0.74) | GLP1RNOD1 | |
| SCHEMBL13184723 | 0.87 | GLP1R (0.55) | GLP1RNOD1CCKARCCKBRSELP | |
| SCHEMBL20034257 | 0.87 | GLP1R (0.55) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | IAPP, GLP1R, ALB | GLP1R 2/4885NOD1 281/4885CCKAR 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.